The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

MyoKardia Inc (MYOK)-Financial and Strategic SWOT Analysis Review

MyoKardia Inc (MYOK)-Financial and Strategic SWOT Analysis Review

Publishing Date : Sep, 2018

License Type :
 

Report Code : 774246

No of Pages : 51

Synopsis
MyoKardia Inc (MYOK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

MyoKardia Inc (MyoKardia) is a clinical stage biopharmaceutical company. The company utilizes precision medicine platform to develop therapies for rare cardiovascular diseases including heritable cardiomyopathies. The company's pipeline products include therapeutic programs for the treatment of heritable cardiomyopathy including hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM). Its lead product candidate, mavacamten, is intended for the treatment of symptomatic oHCM. Its other pipeline product MYK-491 is an orally-administered small molecule to treat genetic DCM caused by mutations in sarcomeric proteins. The company is collaborated with many healthcare organizations for the development and commercialization of product candidates. MyoKardia is headquartered in South San Francisco, California, the US.

MyoKardia Inc Key Recent Developments

Aug 23,2018: New Insights on Disease Burden for Hypertrophic Cardiomyopathy Patients Published in Circulation
Aug 08,2018: MyoKardia reports second quarter 2018 financial results
May 08,2018: MyoKardia Reports First Quarter 2018 Financial Results
Apr 04,2018: MyoKardia Announces Appointment of Taylor C. Harris as Chief Financial Officer
Mar 08,2018: MyoKardia Reports Fourth Quarter and Full Year 2017 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Companies Mentioned
Takeda Pharmaceuticals America Inc
Novartis Corp
Gilead Sciences Inc
Bristol-Myers Squibb Co
Bayer AG
Amgen Inc

Geographical Area
United States
Index
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 - About the Company 6
MyoKardia Inc - Key Facts 6
MyoKardia Inc - Key Employees 7
MyoKardia Inc - Key Employee Biographies 8
MyoKardia Inc - Major Products and Services 9
MyoKardia Inc - History 10
MyoKardia Inc - Company Statement 11
MyoKardia Inc - Locations And Subsidiaries 12
Head Office 12
Other Locations & Subsidiaries 12
Section 2 – Company Analysis 13
Company Overview 13
MyoKardia Inc - Business Description 14
MyoKardia Inc - Corporate Strategy 15
MyoKardia Inc - SWOT Analysis 16
SWOT Analysis - Overview 16
MyoKardia Inc - Strengths 16
MyoKardia Inc - Weaknesses 17
MyoKardia Inc - Opportunities 18
MyoKardia Inc - Threats 19
MyoKardia Inc - Key Competitors 20
Section 3 – Company Financial Ratios 21
Financial Ratios - Capital Market Ratios 21
Financial Ratios - Annual Ratios 22
Performance Chart 24
Financial Performance 24
Financial Ratios - Interim Ratios 25
Financial Ratios - Ratio Charts 26
Section 4 – Company’s Lifesciences Financial Deals and Alliances 27
MyoKardia Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 27
MyoKardia Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 28
MyoKardia Inc, Recent Deals Summary 29
Section 5 – Company’s Recent Developments 30
Aug 23, 2018: New Insights on Disease Burden for Hypertrophic Cardiomyopathy Patients Published in Circulation 30
Aug 08, 2018: MyoKardia reports second quarter 2018 financial results 32
Aug 08, 2018: MyoKardia reports second quarter 2018 financial results 34
Aug 08, 2018: MyoKardia reports second quarter 2018 financial results 36
Aug 08, 2018: MyoKardia reports second quarter 2018 financial results 38
May 08, 2018: MyoKardia Reports First Quarter 2018 Financial Results 40
Apr 04, 2018: MyoKardia Announces Appointment of Taylor C. Harris as Chief Financial Officer 42
Mar 08, 2018: MyoKardia Reports Fourth Quarter and Full Year 2017 Financial Results 43
Jan 19, 2018: MyoKardia Announces Appointment of Cynthia Ladd as General Counsel 45
Nov 02, 2017: MyoKardia Reports Third Quarter 2017 Financial Results and Operational Progress 46
Section 6 – Appendix 47
Methodology 47
Ratio Definitions 47
About GlobalData 51
Contact Us 51
Disclaimer 51
List of Tables
List of Tables
MyoKardia Inc, Key Facts 6
MyoKardia Inc, Key Employees 7
MyoKardia Inc, Key Employee Biographies 8
MyoKardia Inc, Major Products and Services 9
MyoKardia Inc, History 10
MyoKardia Inc, Subsidiaries 12
MyoKardia Inc, Key Competitors 20
MyoKardia Inc, Ratios based on current share price 21
MyoKardia Inc, Annual Ratios 22
MyoKardia Inc, Annual Ratios (Cont...1) 23
MyoKardia Inc, Interim Ratios 25
MyoKardia Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 27
MyoKardia Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 28
MyoKardia Inc, Recent Deals Summary 29
Currency Codes 47
Capital Market Ratios 47
Equity Ratios 48
Profitability Ratios 48
Cost Ratios 49
Liquidity Ratios 49
Leverage Ratios 50
Efficiency Ratios 50

List of Figures
List of Figures
MyoKardia Inc, Performance Chart (2013 - 2017) 24
MyoKardia Inc, Ratio Charts 26
MyoKardia Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 27
MyoKardia Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 28

Published By : GlobalData